Biotech startup Shiru appoints Dr. Ranjani Varadan as Chief Scientific Officer
Formerly Impossible Foods’ VP of R&D and VP of Strategic Ingredients, Varadan assumes new role…
Month: July 2022
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage…
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage…
Akoya to Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
— Tumor control was achieved in four of ten evaluable patients with advanced solid tumors…
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic…
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent…
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it…
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July…
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with…
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis”…
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000…
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
World-class facility supports the company’s growth, and discovery and development of gene therapies for inherited…
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…